Protecting patients from harm: Terfenadine and potential drug therapy interactions

被引:0
|
作者
Morris, LS
Carlson, A
机构
[1] IMS Amer, Dis Treatment & Outcomes Informat Serv, Plymouth Meeting, PA 19462 USA
[2] LLC, Data Intelligent Consultants, Res, Eden Prairie, MN USA
来源
DRUG INFORMATION JOURNAL | 1998年 / 32卷 / 02期
关键词
terfenadine; drug-drug interactions; contraindicated drugs; patient counseling; medication errors;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Communication of drug interactions has been the focus of reports surrounding the use of terfenadine, Two studies reported in the literature indicated that coprescription events between terfenadine and contraindicated drugs occurred despite communications to health professionals regarding potential harm. Recent studies have found that pharmacists frequently dispense such drug combinations without concern or appropriate counseling. Throughout 1996, reports in journals and the public press created concern over drug interactions and the practice of pharmacy. The terfenadine case study highlights weak links in the chain of communication of serious medical information. Early warnings tc, health professionals did not result in the elimination of potential events. Additional communications decreased the rate of coprescription events but did not eliminate them. Current investigations show that these events continue. AIL health care professionals involved in the distribution of pharmaceuticals should use the experiences related to terfenadine as a means to improve their handling of drug interaction and other medical information.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 50 条
  • [21] Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism
    JurimaRomet, M
    Huang, HS
    Beck, DJ
    Li, AP
    TOXICOLOGY IN VITRO, 1996, 10 (06) : 655 - 663
  • [22] Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions
    Rassy, Elie
    Bardet, Aurelie
    Bougacha, Omar
    Gantzer, Laurene
    Lekens, Beranger
    Delaloge, Suzette
    Andre, Fabrice
    Michiels, Stefan
    Pistilli, Barbara
    JAMA NETWORK OPEN, 2022, 5 (12) : E2244849
  • [23] HUMAN CYP3A4 AS A POTENTIAL IN-VITRO SCREENING SYSTEM FOR TERFENADINE DRUG-INTERACTIONS
    KUANG, TY
    MORGAN, A
    LAZAREV, A
    CANTILENA, LR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 139 - 139
  • [24] Potential drug interactions in patients with a history of cancer
    Chen, L.
    Cheung, W. Y.
    CURRENT ONCOLOGY, 2014, 21 (02) : E212 - E220
  • [25] POTENTIAL-DRUG INTERACTIONS IN SURGICAL PATIENTS
    DURRENCE, CW
    DIPIRO, JT
    MAY, JR
    NESBIT, RR
    SISLEY, JF
    COOPER, JW
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1985, 42 (07): : 1553 - 1556
  • [26] Polypharmacy in clozapine patients: Potential for drug interactions
    Mezher, A
    Glen, J
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S229 - S229
  • [27] Potential for drug interactions in hospitalized cancer patients
    Riechelmann, RP
    Moreira, F
    Smaletz, O
    Saad, ED
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (03) : 286 - 290
  • [28] POTENTIAL ANTICOAGULANT DRUG INTERACTIONS IN AMBULATORY PATIENTS
    HULL, JH
    MURRAY, WJ
    BROWN, HS
    WILLIAMS, BO
    CHI, SL
    KOCH, GG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1978, 24 (06) : 644 - 649
  • [29] Potential drug interactions in adult cancer patients
    Rahal, A.
    Gandolfi, R.
    Roller, P.
    Moreau, E.
    Bezie, Y.
    Jardin, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 347 - 347
  • [30] Potential for drug interactions in hospitalized cancer patients
    Rachel Pimenta Riechelmann
    Frederico Moreira
    Òren Smaletz
    Everardo D. Saad
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 286 - 290